Background: Powered exoskeletons are designed to safely facilitate ambulation in patients with spinal cord injury (SCI). We conducted the first meta-analysis of the available published research on the clinical effectiveness and safety of powered exoskeletons in SCI patients.
ReWalk Robotics Ltd. announced the publication of the first systematic review and industry-wide meta-analysis of existing published literature assessing the...
This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results.
The FDA has approved the use of Lyrica (pregabalin) capsules CV from Pfizer for the management of Neuropathic Pain associated...
InVivo Therapeutics Holdings Corp. a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI),announced topline results from the company's INSPIRE 2.0 tudy, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold, a bioresorbable scaffold-based device in development for patients with acute SCI.
Purpose: We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Ipsen announced that Dysport (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) (traumatic or non-traumatic) or multiple sclerosis (MS), who are regularly performing clean intermittent catheterization (CIC).
This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres.
Lineage Cell Therapeutics, Inc. announced that it has entered into an exclusive option and license agreement with Neurgain Technologies, Inc. a medical device company that is commercializing technology developed by neurosurgeons at the University of California San Diego (“UC San Diego”).
Objectives: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to NHL.